A significant number of new specialty medications are on track to be approved in 2013, and some will provide increased competition in certain therapy classes.

New Drug Approvals

 

read all at

http://www.specialtypharmacytimes.com/publications/specialty-pharmacy-times/2013/July_August-2013/Near-Term-Specialty-Pipeline-Highlights-July_August_2013

………

Aimee Tharaldson, PharmD, is a senior clinical consultant in the emerging therapeutics department at Express Scripts. She is responsible for monitoring and analyzing the specialty pharmaceutical pipeline. The emerging therapeutics department produces several proprietary reports on the pipeline for use by Express Scripts’ employees and clients. It is also responsible for the safety program that alerts patients, physicians, and clients to important information regarding serious drug safety alerts and market withdrawals. She contributes to Express Scripts’ Drug Trend Report and plays a key role in developing and maintaining Express Scripts’ specialty drug list. She received her doctor of pharmacy degree from the University of Minnesota, College of Pharmacy, and completed a pharmacy practice residency at the Minneapolis VA Medical Center. –

 

See more at: http://www.specialtypharmacytimes.com/publications/specialty-pharmacy-times/2013/July_August-2013/Near-Term-Specialty-Pipeline-Highlights-July_August_2013#sthash.3n823rAw.dpuf

View original post